-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

Benzinga·09/11/2026 14:06:22
Listen to the news
UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $315 to $337.